A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Haisco Pharmaceutical Group Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd.
002653
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offers its products for anesthesia, analgesia, chronic metabolic, respiratory, autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine an...
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offers its products for anesthesia, analgesia, chronic metabolic, respiratory, autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
